查詢結果分析
相關文獻
- 臺灣20~64歲癌症族群施打流感疫苗之成本效果分析
- 癌症族群施打流感疫苗之成本效益
- 應用噁心嘔吐量表於癌症病童之經驗
- 癌症病人藥事照顧
- 臺南區域癌症患者居家護理使用概況
- Second-Trimester Maternal Serum Levels of Alpha-Fetoprotein, Free β-Subunit of Human Chorionic Gonadotropin and CA-125 in Twin Pregnancy after Multifetal Pregnancy Reduction
- 住院癌症病童父母需要之先期研究
- 最後一段旅程--剖析癌症病人在醫院的垂死歷程
- The Significance of Pain Among Chinese Patients with Cancer in Hong Kong
- Hepatocellular Carcinoma Presenting with Acquired Porphyria: A Case Report and Review of the Literature
頁籤選單縮合
題 名 | 臺灣20~64歲癌症族群施打流感疫苗之成本效果分析 |
---|---|
作 者 | 林筱涵; 柯文謙; 楊宜青; 張育偉; 陳國東; | 書刊名 | 臺灣實證醫學學會會刊 |
卷 期 | 2:1 2009[民98] |
頁 次 | 頁12-25 |
分類號 | 415.138 |
關鍵詞 | 癌症; 流感疫苗; 成本效果; Cancer patients; Influenza vaccine; Cost-effectiveness; |
語 文 | 中文(Chinese) |
中文摘要 | 背景:近年來美國 Advisory Committee on Immunization Practice (ACIP)已提倡針對高危險流感併發症族群施打流感疫苗。因此本篇研究的目的為想評估台灣 20~64歲癌症病患施打流感疫苗之成本效果。材料與方法:使用決策分析模型,模擬 34,112位 20~64歲癌症病患,從醫療觀點與社會觀點評估流感疫苗政策之成本效果。癌症病患的資料來源為台灣 91年癌症登記年報,醫療使用情形資料來源為全民健保資料庫,其餘參數資料來源包括國內、外文獻。本研究比較 20~64歲癌症病患執行流感疫苗政策與不執行流感疫苗政策的成本效果。基準值病患假設為 51歲 (全民健保資料庫,年齡介於 20~64歲且近五年被診斷為癌症之平均年齡 )。結果:由基準值,以醫療觀點看,執行疫苗計劃可節省約台幣 1億 7千萬元;以社會觀點看,執行疫苗計劃可節省約台幣 7億元。由基準值,從醫療觀點看,相較於未執行疫苗計劃方案,每多預防一位癌症病患得流感可節省台幣 66,482元;從社會觀點看,每多預防一位癌症病患得流感可節省台幣 271,572元。最後敏感度分析發現即使基準值變動,從醫療觀點或社會觀點看,執行疫苗計劃仍為成本節省。結論:無論從醫療觀點或社會觀點,給予 20~64歲癌症病患施打流感疫苗都是成本節省且符合成本效果。建議政府單位應加強推動 20~64歲癌症病患施打流感疫苗。 |
英文摘要 | Background:The Advisory Committee on Immunization Practice (ACIP) currently recommends annual vaccination against influenza for all individuals at increased risk of influenza-related complications. Therefore, the purpose of this study was to assess the cost-effectiveness of influenza vaccination of cancer patients in Taiwan. Methods: We used a decision analysis model, from health care system and societal perspective, to estimate the cost-effectiveness of influenza vaccination on 34,112 cancer patients aged 20 to 64. A decision tree used estimates of disease burden, costs obtained from 2002 Taiwan's cancer annual report, resource utilization from National Health Research Institutes Database (NHRID) of 1998-2003, and supplemented with data from Taiwan and other countries’ published articles. The base-case patient was assumed to be a 51-yearold cancer patient (the mean age for NHRID, and 20-64 patients within 5 years of cancer diagnosis.) Results:In base-case, from the health care system perspective, influenza vaccination resulted in savings of NT 17 million; from the societal perspective, influenza vaccination resulted in savings of NT 70 million. In base-case, compared with the no vaccination strategy, from the health care system and societal perspective, the incremental cost-effectiveness ratio was NT 66,482 and NT 271,572 per vaccinated cancer patient gained, respectively. Finally, even the base-case changed, from the health care system and societal perspective, the model was robust. Conclusions:Both from health care system and society indicate that the influenza vaccination would be cost-saving and cost-effective for cancer patients aged 20 to 64 years old in Taiwan. Implementing the influenza immunization programs is recommended for this risk group. |
本系統中英文摘要資訊取自各篇刊載內容。